Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM.

Blood. 2018 Jul 26;132(4):393-404. doi: 10.1182/blood-2016-09-739086. Epub 2018 Mar 22.

2.

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, Huber RM, West HL, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz-Ares Rodríguez LG, Smit EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR.

J Clin Oncol. 2017 Aug 1;35(22):2490-2498. doi: 10.1200/JCO.2016.71.5904. Epub 2017 May 5.

PMID:
28475456
3.

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.

Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR.

Lancet Oncol. 2016 Dec;17(12):1683-1696. doi: 10.1016/S1470-2045(16)30392-8. Epub 2016 Nov 8.

PMID:
27836716
4.

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors.

Pearson AD, Federico SM, Aerts I, Hargrave DR, DuBois SG, Iannone R, Geschwindt RD, Wang R, Haluska FG, Trippett TM, Geoerger B.

Oncotarget. 2016 Dec 20;7(51):84736-84747. doi: 10.18632/oncotarget.12450.

5.

Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients.

Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, Haluska FG.

Leuk Res. 2016 Sep;48:84-91. doi: 10.1016/j.leukres.2016.07.007. Epub 2016 Jul 22.

6.

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.

Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW; EPIC investigators.

Lancet Oncol. 2016 May;17(5):612-21. doi: 10.1016/S1470-2045(16)00080-2. Epub 2016 Apr 12.

PMID:
27083332
7.

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE, Talpaz M, Baccarani M, Müller MC, Li J, Parker WT, Lustgarten S, Clackson T, Haluska FG, Guilhot F, Kantarjian HM, Soverini S, Hochhaus A, Hughes TP, Rivera VM, Branford S.

Blood. 2016 Feb 11;127(6):703-12. doi: 10.1182/blood-2015-08-660977. Epub 2015 Nov 24.

8.

Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma.

Oza AM, Pignata S, Poveda A, McCormack M, Clamp A, Schwartz B, Cheng J, Li X, Campbell K, Dodion P, Haluska FG.

J Clin Oncol. 2015 Nov 1;33(31):3576-82. doi: 10.1200/JCO.2014.58.8871. Epub 2015 Jun 15.

PMID:
26077241
9.

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.

Flaherty LE, Othus M, Atkins MB, Tuthill RJ, Thompson JA, Vetto JT, Haluska FG, Pappo AS, Sosman JA, Redman BG, Moon J, Ribas A, Kirkwood JM, Sondak VK.

J Clin Oncol. 2014 Nov 20;32(33):3771-8. doi: 10.1200/JCO.2013.53.1590. Epub 2014 Oct 20.

10.

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; PACE Investigators.

N Engl J Med. 2013 Nov 7;369(19):1783-96. doi: 10.1056/NEJMoa1306494. Epub 2013 Nov 1.

11.

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui-Nguyen B, Cranmer LD, Reichardt P, Bompas E, Alcindor T, Rushing D, Song Y, Lee RM, Ebbinghaus S, Eid JE, Loewy JW, Haluska FG, Dodion PF, Blay JY.

J Clin Oncol. 2013 Jul 1;31(19):2485-92. doi: 10.1200/JCO.2012.45.5766. Epub 2013 May 28.

PMID:
23715582
12.

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.

Shah NP, Talpaz M, Deininger MW, Mauro MJ, Flinn IW, Bixby D, Lustgarten S, Gozgit JM, Clackson T, Turner CD, Haluska FG, Kantarjian H, Cortes JE.

Br J Haematol. 2013 Aug;162(4):548-52. doi: 10.1111/bjh.12382. Epub 2013 May 21. No abstract available.

13.

A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors.

Gore L, Trippett TM, Katzenstein HM, Boklan J, Narendran A, Smith A, Macy ME, Rolla K; Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC), Narashimhan N, Squillace RM, Turner CD, Haluska FG, Nieder M.

Clin Cancer Res. 2013 Jul 1;19(13):3649-58. doi: 10.1158/1078-0432.CCR-12-3166. Epub 2013 May 9.

14.

Loss of ARF sensitizes transgenic BRAFV600E mice to UV-induced melanoma via suppression of XPC.

Luo C, Sheng J, Hu MG, Haluska FG, Cui R, Xu Z, Tsichlis PN, Hu GF, Hinds PW.

Cancer Res. 2013 Jul 15;73(14):4337-48. doi: 10.1158/0008-5472.CAN-12-4454. Epub 2013 May 6.

15.

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies.

Sonnichsen D, Dorer DJ, Cortes J, Talpaz M, Deininger MW, Shah NP, Kantarjian HM, Bixby D, Mauro MJ, Flinn IW, Litwin J, Turner CD, Haluska FG.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1599-607. doi: 10.1007/s00280-013-2160-7. Epub 2013 Apr 23.

16.

Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M.

N Engl J Med. 2012 Nov 29;367(22):2075-88. doi: 10.1056/NEJMoa1205127.

17.

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.

Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, Rivera VM, Clackson T, Loewy JW, Haluska FG, Demetri GD.

J Clin Oncol. 2012 Jan 1;30(1):78-84. doi: 10.1200/JCO.2011.35.6329. Epub 2011 Nov 7. Erratum in: J Clin Oncol. 2017 Aug 10;35(23):2722.

PMID:
22067397
18.

Molecular pathogenesis of cutaneous melanocytic neoplasms.

Ibrahim N, Haluska FG.

Annu Rev Pathol. 2009;4:551-79. doi: 10.1146/annurev.pathol.3.121806.151541. Review.

PMID:
19400696
19.

Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.

Goel VK, Ibrahim N, Jiang G, Singhal M, Fee S, Flotte T, Westmoreland S, Haluska FS, Hinds PW, Haluska FG.

Oncogene. 2009 Jun 11;28(23):2289-98. doi: 10.1038/onc.2009.95. Epub 2009 Apr 27.

20.

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.

Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G.

Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10. doi: 10.1073/pnas.0712237105. Epub 2008 Feb 19.

21.

Melanoma in the young: differences and similarities with adult melanoma: a case-matched controlled analysis.

Livestro DP, Kaine EM, Michaelson JS, Mihm MC, Haluska FG, Muzikansky A, Sober AJ, Tanabe KK.

Cancer. 2007 Aug 1;110(3):614-24.

22.

Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.

Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ, Jones VE.

J Clin Oncol. 2007 May 20;25(15):2078-85.

PMID:
17513813
23.

Novel inhibitors in the treatment of metastatic melanoma.

Kalinsky K, Haluska FG.

Expert Rev Anticancer Ther. 2007 May;7(5):715-24. Review.

PMID:
17492934
24.

Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).

Krown SE, Niedzwiecki D, Hwu WJ, Hodgson L, Houghton AN, Haluska FG; Cancer and Leukemia Group B.

Cancer. 2006 Oct 15;107(8):1883-90.

25.

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.

Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG; Oblimersen Melanoma Study Group.

J Clin Oncol. 2006 Oct 10;24(29):4738-45. Epub 2006 Sep 11.

PMID:
16966688
26.

Therapeutic targets in melanoma: map kinase pathway.

Haluska FG, Ibrahim N.

Curr Oncol Rep. 2006 Sep;8(5):400-5. Review.

PMID:
16901402
27.

Genetic alterations in signaling pathways in melanoma.

Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2301s-2307s. Review.

28.

Innovations and challenges in melanoma: summary statement from the first Cambridge conference.

Atkins MB, Elder DE, Essner R, Flaherty KT, Gajewski TF, Haluska FG, Hwu P, Keilholz U, Kirkwood JM, Mier JW, Ross MI, Slingluff CL, Sondak VK, Sosman JA, Weinstock MA, King L.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2291s-2296s.

29.

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG.

J Invest Dermatol. 2006 Jan;126(1):154-60.

30.

Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.

Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG; Cancer and Leukemia Group B.

J Immunother. 2006 Jan-Feb;29(1):95-101.

PMID:
16365605
31.

Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.

Linette GP, Zhang D, Hodi FS, Jonasch EP, Longerich S, Stowell CP, Webb IJ, Daley H, Soiffer RJ, Cheung AM, Eapen SG, Fee SV, Rubin KM, Sober AJ, Haluska FG.

Clin Cancer Res. 2005 Nov 1;11(21):7692-9.

32.

Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute.

Katz KA, Jonasch E, Hodi FS, Soiffer R, Kwitkiwski K, Sober AJ, Haluska FG.

Melanoma Res. 2005 Feb;15(1):77-82. Review.

PMID:
15714125
33.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.

35.

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.

Tsao H, Goel V, Wu H, Yang G, Haluska FG.

J Invest Dermatol. 2004 Feb;122(2):337-41.

36.

PTEN signaling pathways in melanoma.

Wu H, Goel V, Haluska FG.

Oncogene. 2003 May 19;22(20):3113-22. Review.

PMID:
12789288
37.

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.

Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G.

Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4712-7. Epub 2003 Apr 7.

39.

Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma.

Tsao H, Millman P, Linette GP, Hodi FS, Sober AJ, Goldberg MA, Haluska FG.

Arch Dermatol. 2002 Jun;138(6):799-802.

PMID:
12056962
40.

Phase II study of paclitaxel and carboplatin for malignant melanoma.

Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG.

Am J Clin Oncol. 2002 Jun;25(3):283-6.

PMID:
12040289
41.

Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data.

Kilbridge KL, Cole BF, Kirkwood JM, Haluska FG, Atkins MA, Ruckdeschel JC, Sock DE, Nease RF Jr, Weeks JC.

J Clin Oncol. 2002 Mar 1;20(5):1311-8.

PMID:
11870174
42.
43.

Patient preferences for adjuvant interferon alfa-2b treatment.

Kilbridge KL, Weeks JC, Sober AJ, Haluska FG, Slingluff CL, Atkins MB, Sock DE, Kirkwood JM, Nease RF.

J Clin Oncol. 2001 Feb 1;19(3):812-23.

PMID:
11157035
45.

Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.

Tsao H, Zhang X, Kwitkiwski K, Finkelstein DM, Sober AJ, Haluska FG.

Arch Dermatol. 2000 Sep;136(9):1118-22.

PMID:
10987867
46.

Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes.

Greenberg DB, Jonasch E, Gadd MA, Ryan BF, Everett JR, Sober AJ, Mihm MA, Tanabe KK, Ott M, Haluska FG.

Cancer. 2000 Jul 15;89(2):356-62. Review.

PMID:
10918166
47.

Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.

Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, Sober AJ, Mihm MC, Tsao H, Langley RG, Cosimi BA, Gadd MA, Tanabe KK, Souba W, Haynes HA, Barnhill R, Osteen R, Haluska FG.

Cancer J. 2000 May-Jun;6(3):139-45.

PMID:
10882328
48.

Melanoma.

Haluska FG, Multani PS.

Cancer Chemother Biol Response Modif. 1999;18:470-88. Review.

PMID:
10800498
49.

Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.

Tsao H, Zhang X, Fowlkes K, Haluska FG.

Cancer Res. 2000 Apr 1;60(7):1800-4.

50.

In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma.

Linette GP, Shankara S, Longerich S, Yang S, Doll R, Nicolette C, Preffer FI, Roberts BL, Haluska FG.

J Immunol. 2000 Mar 15;164(6):3402-12.

Supplemental Content

Loading ...
Support Center